Treatment Options for Pruritic Dermatosis Recalcitrant to Customary Dosage of Bepotastine Besilate : Updosing or Combining with a Sedative Antihistamine

DOI Web Site Web Site 6 References

Bibliographic Information

Other Title
  • 瘙痒性皮膚疾患に対するベポタスチンベシル酸塩の増量およびヒドロキシジンパモ酸塩の追加効果の検討
  • 治療 瘙痒性皮膚疾患に対するベポタスチンベシル酸塩の増量およびヒドロキシジンパモ酸塩の追加効果の検討
  • チリョウ ソウヨウセイ ヒフ シッカン ニ タイスル ベポタスチンベシル サンエン ノ ゾウリョウ オヨビ ヒドロキシジンパモ サンエン ノ ツイカ コウカ ノ ケントウ

Search this article

Description

<p>To compare the efficacy and safety of an increased dosage of bepotastine besilate, which is a non-sedating histamine, with a treatment combining bepotastine besilate and hydroxyzine pamoate in patients with pruritic dermatosis that is recalcitrant to the customary dosage of non-sedating antihistamine. Bepotastine besilate (hereafter bepotastine) 20 mg/day was administered to 70 patients. After 2 weeks of treatment, the customary dosage of bepotastine continued to be administered to patients who showed a favorable response. Non-responsive patients were randomly allocated to two groups receiving either bepotastine alone at twice the customary dosage or bepotastine at the customary dosage combined with hydroxyzine pamoate 25 mg/day. Six weeks later, the severity of dermatosis was assessed by physicians, and the patients submitted a subjective assessment of their pruritus and insomnia via questionnaire. In the final assessment of global improvement, a high degree of efficacy was recognized in both treatment groups with respect to each symptom. However, daytime somnolence and nighttime insomnia worsened in the combination treatment group. Apart from this difference, both doubling the dosage of the non-sedating histamine bepotastine and combining bepotastine with a sedating histamine treatment improved pruritus that was recalcitrant to the customary dosage of bepotastine. Updosing bepotastine may be a favorable option for the treatment of pruritic dermatosis recalcitrant to the customary dosage of bepotastine.</p>

Journal

References(6)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top